AU2021269090A1 - New compositions and methods of treating COVID-19 disease - Google Patents

New compositions and methods of treating COVID-19 disease Download PDF

Info

Publication number
AU2021269090A1
AU2021269090A1 AU2021269090A AU2021269090A AU2021269090A1 AU 2021269090 A1 AU2021269090 A1 AU 2021269090A1 AU 2021269090 A AU2021269090 A AU 2021269090A AU 2021269090 A AU2021269090 A AU 2021269090A AU 2021269090 A1 AU2021269090 A1 AU 2021269090A1
Authority
AU
Australia
Prior art keywords
patients
covid
composition
plerixafor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021269090A
Other languages
English (en)
Inventor
Patrick Berger
Keren BISMUTH
Jérôme BRETON
Isabelle Dupin
Pierre-Olivier Girodet
Chloé JAMES
Renaud PREVEL
Revital RATTENBACH
Valentin SENCIO
Francois Trottein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4living Biotech
Centre Hospitalier De Bordeaux
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Bordeaux
Universite de Lille
Original Assignee
4living Biotech
Centre Hospitalier De Bordeaux
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Bordeaux
Institut Pasteur
Universite de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4living Biotech, Centre Hospitalier De Bordeaux, Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Bordeaux, Institut Pasteur, Universite de Lille filed Critical 4living Biotech
Publication of AU2021269090A1 publication Critical patent/AU2021269090A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021269090A 2020-05-07 2021-05-05 New compositions and methods of treating COVID-19 disease Abandoned AU2021269090A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20173595.8A EP3906922A1 (en) 2020-05-07 2020-05-07 New compositions and methods of treating covid-19 disease
EP20173595.8 2020-05-07
PCT/EP2021/061919 WO2021224356A1 (en) 2020-05-07 2021-05-05 New compositions and methods of treating covid-19 disease

Publications (1)

Publication Number Publication Date
AU2021269090A1 true AU2021269090A1 (en) 2022-12-01

Family

ID=70617050

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021269090A Abandoned AU2021269090A1 (en) 2020-05-07 2021-05-05 New compositions and methods of treating COVID-19 disease

Country Status (9)

Country Link
US (1) US20230157994A1 (https=)
EP (2) EP3906922A1 (https=)
JP (1) JP2023539542A (https=)
KR (1) KR20240073720A (https=)
CN (1) CN116133657A (https=)
AU (1) AU2021269090A1 (https=)
BR (1) BR112022022578A2 (https=)
CA (1) CA3177779A1 (https=)
WO (1) WO2021224356A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517616A (ja) * 2020-03-11 2023-04-26 バイオラインアールエックス・リミテッド 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤
JP2023524522A (ja) * 2020-05-01 2023-06-12 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤
WO2022197625A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2022197627A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2022197626A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
EP4085910A1 (en) * 2021-05-05 2022-11-09 4Living Biotech Use of a compound such as plerixafor for treating a viral pulmonary disease
CN114099531A (zh) * 2021-12-16 2022-03-01 中国人民解放军军事科学院军事医学研究院 一种药物在治疗新型冠状病毒肺炎中的应用
WO2024092069A1 (en) * 2022-10-26 2024-05-02 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors for treatment of neurological diseases
CN121039852A (zh) 2023-06-07 2025-11-28 株式会社Lg新能源 锂金属电池及包含该锂金属电池的电池模组和电池包

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
TW200811138A (en) * 2006-06-12 2008-03-01 Pfizer Prod Inc Pharmaceuticals
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
CN110982945B (zh) * 2020-03-04 2020-06-09 珠海丽珠试剂股份有限公司 一种检测2019新型冠状病毒的核酸组合物、试剂盒以及方法

Also Published As

Publication number Publication date
EP4146195A1 (en) 2023-03-15
JP2023539542A (ja) 2023-09-15
CA3177779A1 (en) 2021-11-11
CN116133657A (zh) 2023-05-16
KR20240073720A (ko) 2024-05-27
EP3906922A1 (en) 2021-11-10
WO2021224356A1 (en) 2021-11-11
US20230157994A1 (en) 2023-05-25
BR112022022578A2 (pt) 2023-01-17

Similar Documents

Publication Publication Date Title
US20230157994A1 (en) New compositions and methods of treating covid-19 disease
US20210309733A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US11052073B1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20210346357A1 (en) Method of treating a patient infected with a coronavirus with a dimethyl amino azetidine amide compound
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
US20230021647A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
Ali et al. The role of tocilizumab in cytokine storm and improving outcomes in COVID-19
US20220363746A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
EP4126961A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP5172679B2 (ja) 呼吸器疾患の治療のためのインターフェロン−λ療法
KR20220139922A (ko) 인터페론 람다로의 코로나바이러스 감염의 치료
US20240317846A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US20230192872A1 (en) Tocilizumab for the treatment of viral infections
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
Roche et al. Therapeutics in hospitalised adult patients with COVID-19
KR20230041097A (ko) SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타
US20260041656A1 (en) Treating pulmonary hypertension based on novel biomarker
US20230109208A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
Sodani Potential pharmacological Therapeutics options for COVID-19
Sriram et al. Drug Repurposing Studies in the Progress to Combat COVID-1
Rezagholizade A comprehensive review on sarilumab in COVID-19
Seckel et al. Understanding the Evolving Pathophysiology of
HK40078901A (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
WO2021229100A1 (en) Bradykinin b2 receptor antagonist for treatment of sars-cov2-infection
Nirola et al. Management of Various Covid-19 Patients and Its Periodontal Considerations

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period